ID   NK101
AC   CVCL_WN95
DR   Wikidata; Q98127913
RX   PubMed=31126350;
CC   Population: Korean.
CC   Characteristics: Possesses fundamental characteristics of natural killer NK (cells). Potential to simultaneously act as a cytokine producer and a cytotoxic effector.
CC   Doubling time: 21.9 +- 2.4 hours (PubMed=31126350).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: STR profile from personal communication of Kim, Sae Won.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 11,12
ST   D18S51: 12,13
ST   D19S433: 14
ST   D21S11: 31.2,32.2
ST   D2S1338: 20,24
ST   D3S1358: 16
ST   D5S818: 10,11
ST   D7S820: 9,12
ST   D8S1179: 11,15
ST   FGA: 21,24
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C4684; Nasal type extranodal NK/T-cell lymphoma
DI   ORDO; Orphanet_86879; Extranodal nasal NK/T cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 10-04-25; Version: 6
//
RX   PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912;
RA   Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C.,
RA   Eom K.-S., Kim S.W.;
RT   "Discovery of a novel natural killer cell line with distinct
RT   immunostimulatory and proliferative potential as an alternative
RT   platform for cancer immunotherapy.";
RL   J. Immunother. Cancer 7:138.1-138.17(2019).
//